Open main menu

Psychiatrienet β

Tranylcypromine-hypericum

Revision as of 08:21, 7 October 2015 by Anoek (talk | contribs)
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine
Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort

Switch medication from tranylcypromine to hypericum.[1] [2]

Nietinrijdenbord.png Stop tranylcypromine
  • Day 1: Decrease the original dose with about 25% every 3 days.
Eenrichtingbord.png Start hypericum
  • Day 15: Start and increase the dose with about 25% of the target dose every 3 days or 50% per week.[3][4][5]
Infobord.png More information
  • After the last dose of tranylcypromine it takes about 14 days to restore the activity of the MAO enzymes
  1. ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. ↑ Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K. The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol. 2008 May;65(5):701-7.
  4. ↑ Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.
  5. ↑ KNMP; Informatorium Medicamentorum 2023; Monografie "tranylcypromine" (Dutch)
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Retrieved from "https://wiki.psychiatrienet.nl/w/index.php?title=Tranylcypromine-hypericum&oldid=7250"